- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02709083
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To assess incidence of major molecular response (MMR) at 12 months.
SECONDARY OBJECTIVES:
I. To assess progression free survival (PFS) at 12 and 24 months.
II. To assess accelerated phase (AP) or blast phase (BP) transformation-free survival at 12 and 24 months.
III. To assess incidence of deep MRs (≥ MR⁴) at 12 months and 24 months.
IV. To assess safety.
V. To assess patient reported outcomes (PRO).
TERTIARY OBJECTIVES:
I. To assess prognostic significance of detecting aberrant myeloid or lymphoid markers on diagnostic bone marrow.
II. To assess ability to enroll subjects who maintain deep molecular remissions in tyrosine kinase inhibitors (TKIs) discontinuation trials.
OUTLINE:
Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
After completion of study treatment, patients are followed up at 2 weeks and then up to 60 months.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Emory University/Winship Cancer Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Newly diagnosed, previously untreated chronic phase chronic myeloid leukemia (CP-CML) (by World Health Organization [WHO] definition) (hydroxyurea permitted up to 7 days prior to enrollment)
- Clinically significant gastrointestinal disease, digestive dysfunction, or surgery that would compromise absorption of oral administration of medications
- Able to give written informed consent and comply with all study visits and procedures
Exclusion Criteria:
- Chronic myeloid leukemia (CML) in AP or BP
- Unable to receive TKI for insurance reasons (uninsurable)
- Refuse or unable to perform telephone or video conferences with research coordinator
- Subjects who are pregnant, breast feeding or sexually active and unwilling to use effective birth control while on treatment with TKI
- Any medical or psychological condition that, in the opinion of the investigator, might interfere with the subject's participation in the trial, poses any additional risk for the subject, or confounds the assessment of the subject
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment-dasatinib, nilotinib, imatinib
Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist.
Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
|
Mündlich gegeben
Andere Namen:
Mündlich gegeben
Andere Namen:
Given orally
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The Proportion of Subjects Who Achieve Major Molecular Response (MMR)
Zeitfenster: At 12 months
|
Response will be measured by a decrease in fusion transcript or protein resulting from the 9;22 chromosomal translocation responsible for formation of the Philadelphia Chromosome (BCR-ABL1) levels on a logarithmic scale.
A 1 log reduction is a drop to below 10%, while a major molecular response (MMR) is defined as a 3 log reduction (0.1%).
|
At 12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Accelerated Phase (AP) or Blast Phase (BP) Free Survival
Zeitfenster: The time of CML diagnosis to the time of transformation to AP or BP, assessed up to 24 months
|
Survival will be defined as the time from CML diagnosis to the time of transformation to accelerated phase (AP) or blast phase (BP).
|
The time of CML diagnosis to the time of transformation to AP or BP, assessed up to 24 months
|
Change in Patient Reported Outcomes (PRO) Score Extracted From the MD Anderson Symptom Inventory-Chronic Myelogenous Leukemia (CML)
Zeitfenster: Baseline to up to 12 months
|
The patient reported outcomes (PRO) score extracted from the MD Anderson Symptom Inventory (MDASI)-Chronic Myelogenous Leukemia (CML) will be determined and intra and inter subject changes will be compared.
|
Baseline to up to 12 months
|
Duration of Adverse Events (AEs) Using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Criteria
Zeitfenster: Up to 30 days after the end-of-treatment
|
Listings of laboratory test results will also be generated, and descriptive statistics summarizing the changes in laboratory tests over time will be presented.
Exposure to drug over time will also be summarized.
The AE incidence rates, as well as the frequency of occurrence of overall toxicity, categorized by toxicity grades (severity) will be described as obtained from subject forms and subject communications.
|
Up to 30 days after the end-of-treatment
|
Frequency of Adverse Events (AEs) Using the Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03) Criteria
Zeitfenster: Up to 30 days after the end-of-treatment
|
Listings of laboratory test results will also be generated, and descriptive statistics summarizing the changes in laboratory tests over time will be presented.
Exposure to drug over time will also be summarized.
The AE incidence rates, as well as the frequency of occurrence of overall toxicity, categorized by toxicity grades (severity) will be described as obtained from subject forms and subject communications.
|
Up to 30 days after the end-of-treatment
|
Progression Free Survival (PFS)
Zeitfenster: The time of CML diagnosis to the time of loss of MMR or loss of hematologic response, assessed up to 24 months
|
Progression free survival (PFS) will be defined as the time from CML diagnosis to the time of loss of major molecular response (MMR) or loss of hematologic response.
|
The time of CML diagnosis to the time of loss of MMR or loss of hematologic response, assessed up to 24 months
|
Severity of Adverse Events (AEs) Using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Criteria
Zeitfenster: Up to 30 days after the end-of-treatment
|
Listings of laboratory test results will also be generated, and descriptive statistics summarizing the changes in laboratory tests over time will be presented.
Exposure to drug over time will also be summarized.
The AE incidence rates, as well as the frequency of occurrence of overall toxicity, categorized by toxicity grades (severity) will be described as obtained from subject forms and subject communications.
|
Up to 30 days after the end-of-treatment
|
The Number of Subjects With Breakpoint Cluster Region-abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL1) Transcript Levels ≤ Deep Molecular Responses (MR⁴)
Zeitfenster: Up to 24 months
|
Descriptive statistics will summarize the changes in breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) testing over time will be presented.
|
Up to 24 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Erkrankungen des Knochenmarks
- Hämatologische Erkrankungen
- Myeloproliferative Erkrankungen
- Leukämie
- Leukämie, Myeloid
- Leukämie, myeloische, chronische, BCR-ABL-positiv
- Leukämie, myeloische, chronische Phase
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Proteinkinase-Inhibitoren
- Imatinibmesylat
- Dasatinib
Andere Studien-ID-Nummern
- IRB00087045
- NCI-2016-00162 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- Winship3143-16 (Andere Kennung: Emory University/Winship Cancer Institute)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Leukämie
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... und andere MitarbeiterUnbekanntAllogene hämatopoetische Stammzelltransplantation | Bedingungen | Mixed-Lineage-Leukemia (MLL)-Rearranged Acute LeukemiaChina
-
Shenzhen Second People's HospitalRekrutierungLeukämie | Myeloisch | Chronisch | BCR-ABL (Breakpoint Cluster Region-Abelson Murine Leukemia) | PositivChina
Klinische Studien zur Imatinibmesylat
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.AbgeschlossenChronisch-myeloischer LeukämieChina
-
Duke UniversityNovartis PharmaceuticalsAbgeschlossenGlioblastom | GliosarkomVereinigte Staaten
-
Dr. Jurjan AmanExvastat Ltd.; Simbec-Orion Group; KABS laboratoriesBeendetCovid19 | Endotheliale Dysfunktion | Akutes Lungenversagen | Akutes Lungenversagen | LungenödemNiederlande
-
M.D. Anderson Cancer CenterNovartis PharmaceuticalsBeendetSolider Krebs | SchilddrüsenkrebsVereinigte Staaten
-
Chengdu Zenitar Biomedical Technology Co., LtdAbgeschlossenDiffuses großzelliges B-Zell-Lymphom, DLBCLChina
-
IlDong Pharmaceutical Co LtdAbgeschlossenGesundKorea, Republik von
-
Medical University of South CarolinaColumbia UniversityAbgeschlossen
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.AbgeschlossenChronisch-myeloischer Leukämie | Magen-Darm-StromatumorIndien
-
Calgent Biotechnology Co., LtdAbgeschlossenResistente oder refraktäre solide TumorenVereinigte Staaten, Taiwan
-
Pathway Therapeutics, Inc.AbgeschlossenMalignomeVereinigte Staaten